NDA 021862 · Harrow Eye
Nevanac
Nepafenac · Ophthalmic · Nonsteroidal Anti-inflammatory Drug
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: Nov 4, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2005
Aug 19, 2005
Approved uses
1
Original approval plus efficacy supplements
Registered trials
57
12 Phase 3, 1 recruiting
FAERS reports
893
546 serious, 21 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 5, 2024.
NEVANAC ® 0.1% is indicated for the treatment of pain and inflammation associated with cataract surgery. NEVANAC is a nonsteroidal, anti-inflammatory prodrug indicated for the treatment of pain and inflammation associated with cataract surgery. ( 1 )
Mechanism: After topical ocular dosing, nepafenac penetrates the cornea and is converted by ocular tissue hydrolases to amfenac, an NSAID. Amfenac is thought to inhibit the action of prostaglandin H synthase (cyclooxygenase), an enzyme required for prostaglandin production.
Therapeutic areas: Pain and anesthesia
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 19, 2005 Original approval · Type 1 - New Molecular Entity · priority review NovelReviewLetterLabel
1 products under this application
- NEVANAC · NEPAFENAC 0.1% · SUSPENSION/DROPS, OPHTHALMIC · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Nepafenac" as an intervention, any sponsor and status, largest first.
- Confirmatory Study Nepafenac 0.3%Pivotal-lookingCompleted
Alcon ResearchIndustry
NCT01109173 · 2,120 participants · Start Jun 2010 · Primary completion May 2011
Drug: Nepafenac Ophthalmic Suspension, 0.3%; Nepafenac Ophthalmic Suspension, 0.1% · For: Cataract
Sites: Fort Worth, Texas
- Nepafenac 0.3% Two StudyPivotal-lookingCompleted
Alcon ResearchIndustry
NCT01318499 · 1,342 participants · Start Mar 2011 · Primary completion Sep 2011
Drug: Nepafenac Ophthalmic Suspension, 0.3%; Nepafenac Ophthalmic Suspension, 0.1% · For: Cataract
Sites: Fort Worth, Texas
- Nepafenac Once Daily for Macular Edema - Study 1Pivotal-lookingCompleted
Alcon ResearchIndustry
NCT01853072 · 881 participants · Start Jun 2013 · Primary completion May 2015
Drug: Nepafenac Ophthalmic Suspension, 0.3%; Prednisolone acetate · For: Non-Proliferative Diabetic Retinopathy; Cataract
- Nepafenac Once Daily for Macular Edema - Study 2Pivotal-lookingCompleted
Alcon ResearchIndustry
NCT01872611 · 819 participants · Start Jun 2013 · Primary completion May 2015
Drug: Nepafenac Ophthalmic Suspension, 0.3%; Prednisolone acetate · For: Non-Proliferative Diabetic Retinopathy; Cataract
- Prospective Study With Adjunctive Once Daily Topical Nepafenac 0.3% Versus PlaceboPivotal-lookingCompleted
Intuor Technologies, Inc.Industry
NCT03025945 · 662 participants · Start Oct 2013 · Primary completion Jan 2017
Drug: Nepafenac 0.3%; Saline Solution · For: Cystoid Macular Edema
- Cataract Surgery and Inflammation - the Role for Preoperative NSAIDs (Pre-CIN)Pivotal-lookingStatus unknown
Oslo University HospitalAcademic, hospital or other
NCT05331690 · 500 participants (planned) · Start Nov 25, 2022 · Primary completion Aug 2023
Drug: Nepafenac Ophthalmic; Nepafenac Ophthalmic and 1 more · For: Cataract Surgery
Sites: Oslo, Norway
- Clinical Endpoint Study of Nepafenac 0.3% Opthalmic SuspensionPivotal-lookingCompleted
Actavis Inc.Industry
NCT03499873 · 448 participants · Start Mar 28, 2018 · Primary completion Oct 31, 2018
Drug: Nepafenac 0.3% Oph Susp; Placebos and 1 more · For: Cataract
Sites: Dallas, Texas
- Effect of Nepafenac Eye Drops on Intraocular Pressure in Normal EyesPivotal-lookingCompleted
Dr T V Patel Eye InstituteAcademic, hospital or other
NCT01995890 · 327 participants · Start Dec 2012 · Primary completion Feb 2013
Drug: nepafenac · For: Intraocular Pressure
Sites: Vadodara, India
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective124
- treatment failure107
- off label use54
- vision blurred52
- cataract46
- visual acuity reduced44
- visual impairment40
- eye pain35
- macular oedema35
- nausea33
- fatigue32
- headache30
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2005 | 4 |
| 2006 | 64 |
| 2007 | 11 |
| 2008 | 14 |
| 2009 | 13 |
| 2010 | 17 |
| 2011 | 18 |
| 2012 | 47 |
| 2013 | 28 |
| 2014 | 39 |
| 2015 | 51 |
| 2016 | 121 |
| 2017 | 46 |
| 2018 | 51 |
| 2019 | 39 |
| 2020 | 141 |
| 2021 | 36 |
| 2022 | 38 |
| 2023 | 44 |
| 2024 | 32 |
| 2025 | 30 |
| 2026 | 9 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Nevanac (Nepafenac)
2024 spending
$1.7M
Beneficiaries
1,397
3,362 claims
Per beneficiary
$1,235
$109.81 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $1,544,916 |
| 2024 | $1,725,616 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Topical non-steroidal anti-inflammatory agents for diabetic cystoid macular oedema.
Sahoo S, Barua A, Myint KT, et al. · Cochrane Database Syst Rev 2015 · Research Support, Non-U.S. Gov't, Systematic Review
- Topical nepafenec in eyes with noncentral diabetic macular edema.
Friedman SM, Almukhtar TH, Baker CW, et al. · Retina 2015 · Clinical Trial, Phase II, Multicenter Study
- Topical NSAIDs effect on corneal sensitivity.
Singer DD, Kennedy J, Wittpenn JR · Cornea 2015 · Randomized Controlled Trial
- COMPARISON OF THE EFFECTS OF EIGHT DIFFERENT TOPICAL NONSTEROIDAL ANTI-INFLAMMATORY DRUGS ON REDUCING INTRAVITREAL INJECTION-INDUCED PAIN.
SakallioĞlu AK, Kaya S, Garp R, et al. · Retina 2024 · Randomized Controlled Trial, Comparative Study
- Post-Intravitreal injection pain reduction using topical NSAIDS: A comparative study.
Shtayer C, Lily Okrent Smolar A, Elmalak M, et al. · Eur J Ophthalmol 2025 · Randomized Controlled Trial, Comparative Study
- Intraindividual comparison of nepafenac 0.3% for the prevention of macular edema after phacoemulsification.
Tzelikis PF, Morato CS, Neves NT, et al. · J Cataract Refract Surg 2018 · Randomized Controlled Trial
Sponsor: Harrow Eye
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.